Zevra Therapeutics (ZVRA) Cash from Financing Activities (2014 - 2026)

Zevra Therapeutics' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$52.8 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 3385.87% year-over-year to -$52.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.3 million (down 151.33% YoY) and the FY2025 annual result came in at $12.1 million, down 85.31% from the prior year.
• Cash from Financing Activities was -$52.8 million for Q1 2026 at Zevra Therapeutics, down from $2.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $64.8 million in Q3 2024 and bottomed at -$52.8 million in Q1 2026.
• A 5-year average of $4.6 million and a median of $1.4 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 7800.59% — and 2026, when it tumbled 3385.87%.
• Zevra Therapeutics' Cash from Financing Activities stood at -$325000.0 in 2022, then soared by 1639.69% to $5.0 million in 2023, then sank by 84.09% to $796000.0 in 2024, then surged by 219.85% to $2.5 million in 2025, then plunged by 2174.0% to -$52.8 million in 2026.
• Business Quant data shows ZVRA's Cash from Financing Activities at -$52.8 million in Q1 2026, $2.5 million in Q4 2025, and $6.5 million in Q3 2025.